Darifenacin and Posaconazole: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Strong CYP3A4 inhibition increases darifenacin exposure.
Clinical significance and safety
Darifenacin and Posaconazole: The reviewed UK Emselex information contraindicates concurrent strong CYP3A4 inhibitors. The prescriber should select an alternative because antimuscarinic adverse effects may increase. Inability to pass urine or severe constipation needs prompt advice. Do not attempt to manage this interaction yourself.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.